

Meeting Title	Board of Directors		
Date	18 March 2021	Agenda item:	Bo.3.21.15

Change of Representation on Board of Pathology Joint venture

Presented by	John Holden, Director of Strategy & Integration		
Author	John Holden, Director of Strategy & Integration		
Lead Director	John Holden, Director of Strategy & Integration		
Purpose of the paper	To seek Board approval to change BTHFT's representation on the Board of our pathology joint venture		
Key control	Strategic Objective 1 – outstanding care Strategic Objective 5 – effective collaboration		
Action required	To approve		
Previously discussed at/informed by	Executive Team Meeting – 8 February 2021		
Previously approved at:	Committee/Group	Date	
	N/A		

Summary

- Bradford Teaching Hospitals is in a joint venture with Airedale NHS FT (ANFT) and Harrogate and District NHS FT (HDFT) for the provision of pathology services. The joint venture is delivered through two limited liability partnerships: Integrated Pathology Solutions (IPS) LLP, and Integrated Laboratory Solutions (ILS) LLP. A single Board oversees the running of IPS and ILS.
- Since the inception of the joint venture, Bradford Teaching Hospitals has been represented by two Executive Directors on the IPS/ILS Board – these were Dr Bryan Gill (the then Chief Medical officer) and John Holden (Director of Strategy & Integration). Chairmanship of the Board rotates between the partner organisations, and John Holden was the first Chair of the JV Board (Airedale and now Harrogate have subsequently taken a turn) at a time when the focus was very much on establishing and stabilising the JV and working through the practicalities of a “startup”.
- On the retirement of Dr Gill at the end of 2020 it was agreed that he should be replaced by Matthew Horner, BTHFT's Director of Finance. This was a very good fit with the balance of the JV Board which had lost some financial expertise as Airedale's Finance Director was moving to a different role and leaving the JV Board.
- Increasingly the focus of the JV will be on greater integration and delivery of a single approach across each of the modalities (microbiology, histopathology and so on). This will be significantly enabled by digital working and in time the introduction of a new Laboratory Information System. At the same time there is significant work underway across West Yorkshire & Harrogate to develop a consolidated approach to pathology, in line with the recommendations of Lord Carter. Again, this will be enabled by digital collaboration. Yet the JV Board does not have a digital leader as part of its current membership.
- It has therefore been agreed by the BTHFT Executive Team that Dr Paul Rice, Chief Digital & Informatics Officer, should replace John Holden as one of our two Directors on the JV, alongside Matthew Horner. This will also be a very good addition to balance the skills and experience at the JV Board and the proposal was welcomed in the JV Board's most recent meeting on 9 March, recognising of course that the final decision about representation rests with the Trust.

Meeting Title	Board of Directors		
Date	18 March 2021	Agenda item:	Bo.3.21.15

Recommendation
<p>The Board of Directors is requested to approve the proposal that Dr Paul Rice should replace John Holden as one of the Trust's two representatives on the Board of the IPS/ILS LLPs.</p>